Novavax's president and CEO, Stanley Erck, will head off to retirement later this month, and the Maryland-based vaccine specialist has officially named his replacement.
According to Novavax, John C. Jacobs will succeed Erck as president, CEO and a member of the Board of Directors, effective January 23, 2023.
Jacobs comes to Novavax from Harmony Biosciences — a Pennsylvania-based drugmaker with a focus on rare neurological disorders — where he has served as president, CEO and board member since June 2018.
Erck, who has headed Novavax since April 2011, was responsible for bringing the company's COVID-19 vaccine — its first commercial product – to market in over 40 countries around the world. The vaccine, Adjuvanted, was granted EUA by the U.S. FDA this past summer.